Tag : Ibrutinib

Latest News

Janssen busca ampliar el uso de IMBRUVICA® (ibrutinib) en combinación con rituximab para pacientes con leucemia linfocítica crónica (LLC) no tratada con anterioridad

Newsemia
BEERSE, Bélgica–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson ha anunciado hoy la presentación de una solicitud de variación de Tipo II a la...
Latest News

X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor in Combination with Ibrutinib for the Treatment of Waldenström’s Macroglobulinemia (WM)

Newsemia
CAMBRIDGE, Mass.–(BUSINESS WIRE)–X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today...
Pharma / Biotech

Itraconazole increases ibrutinib exposure ten-fold and reduces inter-individual variation – A potentially beneficial drug-drug interaction.

Newsemia
Related Articles Itraconazole increases ibrutinib exposure ten-fold and reduces inter-individual variation – A potentially beneficial drug-drug interaction. Clin Transl Sci. 2019 Oct 30;: Authors: Tapaninen...
Pharma / Biotech

A rapid and sensitive method for quantification of ibrutinib in rat plasma by UPLC-ESI-MS/MS: validation and application to pharmacokinetic studies of a novel ibrutinib nanocrystalline.

Newsemia
Related Articles A rapid and sensitive method for quantification of ibrutinib in rat plasma by UPLC-ESI-MS/MS: validation and application to pharmacokinetic studies of a novel...
Neurology

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.

Newsemia
Related Articles Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy